OPX Biotechnologies and Evonik Industries today announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for Opxbio to use its proprietary EDGE (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
Compelling solutions through strategic partnerships
BASF sells a majority stake in its coatings business to the investor Carlyle.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
